Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Dattoli

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Oncology (Williston Park, N.Y.)|August 25, 2007
Reviving the acid phosphatase test for prostate cancerAl Taira, Gregory Merrick, Kent Wallner, et al.
Dose-Response : a Publication of International Hormesis Society|April 22, 2020
Replacing LNT: The Integrated LNT-Hormesis ModelCara Y Kaminski, Michael Dattoli, Joseph M Kaminski
Cancer|June 20, 2007
Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk featuresMichael Dattoli, Kent Wallner, Lawrence True, et al.
Cancer|February 6, 2003
Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphataseMichael Dattoli, Kent Wallner, Lawrence True, et al.
Urology|February 27, 2007
Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extensionMichael Dattoli, Kent Wallner, Lawrence True, et al.
Journal of Oncology|September 18, 2010
Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapyMichael Dattoli, Kent Wallner, Lawrence True, et al.
Urology|February 5, 2008
Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapyL Christine Fang, Michael Dattoli, Al Taira, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Oncology (Williston Park, N.Y.)|August 25, 2007
Reviving the acid phosphatase test for prostate cancerAl Taira, Gregory Merrick, Kent Wallner, et al.
Dose-Response : a Publication of International Hormesis Society|April 22, 2020
Replacing LNT: The Integrated LNT-Hormesis ModelCara Y Kaminski, Michael Dattoli, Joseph M Kaminski
Cancer|June 20, 2007
Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk featuresMichael Dattoli, Kent Wallner, Lawrence True, et al.
Cancer|February 6, 2003
Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphataseMichael Dattoli, Kent Wallner, Lawrence True, et al.
Urology|February 27, 2007
Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extensionMichael Dattoli, Kent Wallner, Lawrence True, et al.
Journal of Oncology|September 18, 2010
Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapyMichael Dattoli, Kent Wallner, Lawrence True, et al.
Urology|February 5, 2008
Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapyL Christine Fang, Michael Dattoli, Al Taira, et al.
Pageof 1